{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T05:22:30Z","timestamp":1767504150829,"version":"3.48.0"},"reference-count":27,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005315","name":"Natural Science Foundation of Ningbo","doi-asserted-by":"publisher","award":["2024J305"],"award-info":[{"award-number":["2024J305"]}],"id":[{"id":"10.13039\/501100005315","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82400170"],"award-info":[{"award-number":["82400170"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Zhejiang Provincial Medical Science and Technology Project","award":["2025KY1329"],"award-info":[{"award-number":["2025KY1329"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Higher-risk myelodysplastic syndromes (HR-MDS) carry a high risk of progression to acute myeloid leukemia and poor overall survival. Hypomethylating agents (HMAs), such as azacitidine, remain the standard of care but have limited efficacy. A 15-day venetoclax-azacitidine regimen has shown promising objective response rates (ORR) and potential as a bridge to allogeneic hematopoietic stem cell transplantation (HSCT) in relapsed\/refractory HR-MDS. We conducted a prospective multicenter trial to evaluate its efficacy and safety in previously untreated patients. Methods: This multicenter prospective study enrolled treatment-na\u00efve HR-MDS patients (IPSS-R &gt; 3.5). Venetoclax was administered on days 1\u201315 (escalated from 100 to 400 mg), combined with azacitidine (75 mg\/m2) on days 1\u20137 of each 28-day cycle. The primary endpoint was ORR (2006 IWG criteria); secondary endpoints included complete remission (CR), overall survival (OS), and AML progression. Results: Twenty-eight patients (median age: 63 years) were enrolled, with a median follow-up of 8.5 months. ORR was 85.7% per 2006 IWG (CR: 35.7%, marrow CR: 50.0%), and 78.6% per 2023 IWG (CR: 35.7%). Responses were consistent across molecular and IPSS-R subgroups. Median OS was not reached. High neutrophil count and high cytogenetic risk were favorable factors; TP53 mutation\/deletion was an adverse prognostic marker. Grade 3\u20134 hematologic toxicities included neutropenia (96.4%), anemia (71.4%), and thrombocytopenia (64.3%). Serious adverse events (35.7%) were mainly infections. No dose-limiting or unexpected toxicities were observed. Conclusions: The 15-day venetoclax plus azacitidine regimen demonstrated high efficacy and manageable toxicity in treatment-na\u00efve HR-MDS. It may be particularly beneficial for patients with high neutrophil counts, adverse cytogenetics, or those eligible for HSCT, supporting further investigation in larger trials.<\/jats:p>","DOI":"10.3390\/cancers18010159","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T09:18:56Z","timestamp":1767345536000},"page":"159","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["15-Day Duration of Venetoclax Combined with Azacitidine in Treatment-Naive Higher-Risk Myelodysplastic Syndromes: A Prospective Multicenter Study"],"prefix":"10.3390","volume":"18","author":[{"given":"Binbin","family":"Lai","sequence":"first","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Ningbo University, 59 Liuting Street, Ningbo 315000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Mei","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China"},{"name":"Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Ningbo University, 59 Liuting Street, Ningbo 315000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieguang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Ningbo University, 59 Liuting Street, Ningbo 315000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Ningbo University, 59 Liuting Street, Ningbo 315000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixia","family":"Sheng","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Ningbo University, 59 Liuting Street, Ningbo 315000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanhao","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Ningbo University, 59 Liuting Street, Ningbo 315000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Ningbo University, 59 Liuting Street, Ningbo 315000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongcheng","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Ningbo University, 59 Liuting Street, Ningbo 315000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanzhuo","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"De","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyuan","family":"Mai","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huafeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liya","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China"},{"name":"Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinjun","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Wu","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huifang","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Zhejiang Provincial Tongde Hospital, 234 Gucui Road, Hangzhou 310012, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, 3 Qingchun East Road, Hangzhou 310016, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5912-2633","authenticated-orcid":false,"given":"Baodong","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Hematology, Zhejiang Provincial Hospital of Traditional Chinese Medicine, 54 Youdian Road, Hangzhou 310009, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China"},{"name":"Myelodysplastic Syndromes Diagnosis and Therapy Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3411-3666","authenticated-orcid":false,"given":"Guifang","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Department of Hematology, The First Affiliated Hospital of Ningbo University, 59 Liuting Street, Ningbo 315000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMra1904794","article-title":"Myelodysplastic Syndromes","volume":"383","author":"Cazzola","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"ref_3","first-page":"339","article-title":"Treatment of high-risk myelodysplastic syndromes","volume":"110","year":"2025","journal-title":"Haematologica"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for Myelodysplastic Syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/PPO.0000000000000662","article-title":"Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes: The Current Landscape and Future Directions","volume":"29","author":"Sabile","year":"2023","journal-title":"Cancer J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"ref_7","first-page":"460.e1","article-title":"Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect\u00ae Myeloid Disease Registry: Potential Barriers to Care","volume":"29","author":"Tomlinson","year":"2023","journal-title":"Transpl. Cell. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1200\/JCO.2010.31.0854","article-title":"Hypomethylating agents and other novel strategies in myelodysplastic syndromes","volume":"29","author":"Fenaux","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: Mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1056\/NEJMoa2119771","article-title":"Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy","volume":"386","author":"Liu","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1016\/j.clml.2021.01.024","article-title":"Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis","volume":"21","author":"Liu","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.2217\/fon-2021-0936","article-title":"Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: Why are we not achieving the promise of clinical trials?","volume":"17","author":"Zeidan","year":"2021","journal-title":"Future Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1182\/blood-2018-03-828269","article-title":"BCL-2 inhibition in AML: An unexpected bonus?","volume":"132","author":"Konopleva","year":"2018","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/leu.2015.179","article-title":"Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients","volume":"30","author":"Jilg","year":"2016","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/hon.3112","article-title":"15-days duration of venetoclax combined with azacitidine in the treatment of relapsed\/refractory high-risk myelodysplastic syndromes: A retrospective single-center study","volume":"41","author":"Mei","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.2024025464","article-title":"Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes","volume":"145","author":"Garcia","year":"2025","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"ref_21","first-page":"2047","article-title":"Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1016\/S2352-3026(22)00216-2","article-title":"Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: Phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1\u20132 study","volume":"9","author":"Bazinet","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood.2024027217","article-title":"Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML","volume":"145","author":"Lu","year":"2025","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","author":"Gore","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1182\/blood.2024025271","article-title":"How I Treat Higher-Risk MDS","volume":"145","author":"Mina","year":"2025","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41408-022-00744-z","article-title":"Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome","volume":"12","author":"Komrokji","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1182\/blood-2025-235","article-title":"Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-na\u00efve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)","volume":"146","author":"Platzbecker","year":"2025","journal-title":"Blood"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/1\/159\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T05:18:56Z","timestamp":1767503936000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/1\/159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["cancers18010159"],"URL":"https:\/\/doi.org\/10.3390\/cancers18010159","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2026,1,2]]}}}